Regeneron Pharmaceuticals Inc REGN
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
Regeneron Pharmaceuticals Inc is a large-cap company in the Healthcare sector (Biotechnology), with a market value of $75.7B, based in the USA.
It employs about 15,410 people and has been listed since Apr 02, 1991.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
Cheap or expensive? relatively cheap
Its price-to-earnings (P/E) is 18.2 versus 31.6 for the median of the Healthcare sector in our universe (22 companies) — relatively cheap.
Revenue is growing 17% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 14.5 — they expect higher earnings.
The average analyst price target is 853.19, 16% above the current price (their view, not ours).
The stock sits at 61% of its one-year range (0% = the low, 100% = the high).
The risks
- No risk flags were detected from the data we have.
Strengths
- ✅ Profitable — 30 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Buys back its shares (2% fewer shares in a year).
- ✅ More cash than debt.
- ✅ Most analysts rate it buy (18 vs 1).
- ✅ Revenue is growing 17% a year.
- ✅ Pays a dividend (0.5% a year).
What changed this week
Over the past week the stock fell 6.7% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
This week's news
- Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets finance.yahoo.com · 2026-10-03
- Sanofi, Regeneron Expand Immunology Alliance With New Antibodies finance.yahoo.com · 2026-10-02
- Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks finance.yahoo.com · 2026-10-01
- Why Regeneron (REGN) Stock Is Trading Lower Today finance.yahoo.com · 2026-10-01
- Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment finance.yahoo.com · 2026-10-01
- Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) finance.yahoo.com · 2026-10-01
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.